Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 10,876

Sort by:

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drug pipeline report- 2020 is an annual R&D review of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (...

October 2019 40 pages

Hospital Acquired Pneumonia (HAP) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Hospital Acquired Pneumonia (HAP) Drug pipeline report- 2020 is an annual R&D review of Hospital Acquired Pneumonia (HAP) pipeline candidates. The report presents the current status of all major Hospi...

October 2019 80 pages

Human Parainfluenza Virus Type 3 Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Human Parainfluenza Virus Type 3 Infections Drug pipeline report- 2020 is an annual R&D review of Human Parainfluenza Virus Type 3 Infections pipeline candidates. The report presents the current statu...

October 2019 40 pages

Influenza A Virus, H3N2 Subtype Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Influenza A Virus, H3N2 Subtype Infections Drug pipeline report- 2020 is an annual R&D review of Influenza A Virus, H3N2 Subtype Infections pipeline candidates. The report presents the current status...

October 2019 120 pages

Influenza A Virus, H5N1 Subtype Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Influenza A Virus, H5N1 Subtype Infections Drug pipeline report- 2020 is an annual R&D review of Influenza A Virus, H5N1 Subtype Infections pipeline candidates. The report presents the current status...

October 2019 130 pages

Influenza A Virus, H7N9 Subtype Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Influenza A Virus, H7N9 Subtype Infections Drug pipeline report- 2020 is an annual R&D review of Influenza A Virus, H7N9 Subtype Infections pipeline candidates. The report presents the current status...

October 2019 60 pages

Influenzavirus B Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Influenzavirus B Infections Drug pipeline report- 2020 is an annual R&D review of Influenzavirus B Infections pipeline candidates. The report presents the current status of all major Influenzavirus B...

October 2019 100 pages

Japanese Encephalitis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Japanese Encephalitis Drug pipeline report- 2020 is an annual R&D review of Japanese Encephalitis pipeline candidates. The report presents the current status of all major Japanese Encephalitis therape...

October 2019 40 pages

Klebsiella pneumoniae Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Klebsiella pneumoniae Infections Drug pipeline report- 2020 is an annual R&D review of Klebsiella pneumoniae Infections pipeline candidates. The report presents the current status of all major Klebsie...

October 2019 100 pages

Lassa Fever (Lassa Hemorrhagic Fever) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Lassa Fever (Lassa Hemorrhagic Fever) Drug pipeline report- 2020 is an annual R&D review of Lassa Fever (Lassa Hemorrhagic Fever) pipeline candidates. The report presents the current status of all maj...

October 2019 50 pages

Leishmaniasis (Kala-Azar) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Leishmaniasis (Kala-Azar) Drug pipeline report- 2020 is an annual R&D review of Leishmaniasis (Kala-Azar) pipeline candidates. The report presents the current status of all major Leishmaniasis (Kala-A...

October 2019 100 pages

Lyme Disease Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Lyme Disease Drug pipeline report- 2020 is an annual R&D review of Lyme Disease pipeline candidates. The report presents the current status of all major Lyme Disease therapeutic compounds. Detailed in...

October 2019 50 pages

Lymphatic Filariasis (Elephantiasis) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Lymphatic Filariasis (Elephantiasis) Drug pipeline report- 2020 is an annual R&D review of Lymphatic Filariasis (Elephantiasis) pipeline candidates. The report presents the current status of all major...

October 2019 30 pages

Marburgvirus Infections (Marburg Hemorrhagic Fever) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Marburgvirus Infections (Marburg Hemorrhagic Fever) Drug pipeline report- 2020 is an annual R&D review of Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline candidates. The report presents t...

October 2019 60 pages

Measles Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Measles Drug pipeline report- 2020 is an annual R&D review of Measles pipeline candidates. The report presents the current status of all major Measles therapeutic compounds. Detailed insights into Mea...

October 2019 40 pages

Meningitis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Meningitis Drug pipeline report- 2020 is an annual R&D review of Meningitis pipeline candidates. The report presents the current status of all major Meningitis therapeutic compounds. Detailed insights...

October 2019 30 pages

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Drug pipeline report- 2020 is an annual R&D review of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline candidate...

October 2019 40 pages

Middle East Respiratory Syndrome (MERS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Middle East Respiratory Syndrome (MERS) Drug pipeline report- 2020 is an annual R&D review of Middle East Respiratory Syndrome (MERS) pipeline candidates. The report presents the current status of all...

October 2019 70 pages

Mumps Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Mumps Drug pipeline report- 2020 is an annual R&D review of Mumps pipeline candidates. The report presents the current status of all major Mumps therapeutic compounds. Detailed insights into Mumps pip...

October 2019 40 pages

Neisseria meningitidis Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Neisseria meningitidis Infections Drug pipeline report- 2020 is an annual R&D review of Neisseria meningitidis Infections pipeline candidates. The report presents the current status of all major Neiss...

October 2019 70 pages

Osteomyelitis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Osteomyelitis Drug pipeline report- 2020 is an annual R&D review of Osteomyelitis pipeline candidates. The report presents the current status of all major Osteomyelitis therapeutic compounds. Detailed...

October 2019 30 pages

Pertussis (Whooping Cough) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Pertussis (Whooping Cough) Drug pipeline report- 2020 is an annual R&D review of Pertussis (Whooping Cough) pipeline candidates. The report presents the current status of all major Pertussis (Whooping...

October 2019 70 pages

Poliomyelitis (Polio) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Poliomyelitis (Polio) Drug pipeline report- 2020 is an annual R&D review of Poliomyelitis (Polio) pipeline candidates. The report presents the current status of all major Poliomyelitis (Polio) therape...

October 2019 70 pages

Progressive Multifocal Leukoencephalopathy Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Progressive Multifocal Leukoencephalopathy Drug pipeline report- 2020 is an annual R&D review of Progressive Multifocal Leukoencephalopathy pipeline candidates. The report presents the current status...

October 2019 40 pages

Pseudomonas aeruginosa Pneumonia Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Pseudomonas aeruginosa Pneumonia Drug pipeline report- 2020 is an annual R&D review of Pseudomonas aeruginosa Pneumonia pipeline candidates. The report presents the current status of all major Pseudom...

October 2019 40 pages

Pyelonephritis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Pyelonephritis Drug pipeline report- 2020 is an annual R&D review of Pyelonephritis pipeline candidates. The report presents the current status of all major Pyelonephritis therapeutic compounds. Detai...

October 2019 60 pages

Q Fever Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Q Fever Drug pipeline report- 2020 is an annual R&D review of Q Fever pipeline candidates. The report presents the current status of all major Q Fever therapeutic compounds. Detailed insights into Q F...

October 2019 20 pages

Rabies Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Rabies Drug pipeline report- 2020 is an annual R&D review of Rabies pipeline candidates. The report presents the current status of all major Rabies therapeutic compounds. Detailed insights into Rabies...

October 2019 60 pages

Rhinovirus Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Rhinovirus Infections Drug pipeline report- 2020 is an annual R&D review of Rhinovirus Infections pipeline candidates. The report presents the current status of all major Rhinovirus Infections therape...

October 2019 50 pages

Rotavirus Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Rotavirus Infections Drug pipeline report- 2020 is an annual R&D review of Rotavirus Infections pipeline candidates. The report presents the current status of all major Rotavirus Infections therapeuti...

October 2019 50 pages

Schistosomiasis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Schistosomiasis Drug pipeline report- 2020 is an annual R&D review of Schistosomiasis pipeline candidates. The report presents the current status of all major Schistosomiasis therapeutic compounds. De...

October 2019 40 pages

Severe Acute Respiratory Syndrome (SARS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Severe Acute Respiratory Syndrome (SARS) Drug pipeline report- 2020 is an annual R&D review of Severe Acute Respiratory Syndrome (SARS) pipeline candidates. The report presents the current status of a...

October 2019 70 pages

Smallpox Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Smallpox Drug pipeline report- 2020 is an annual R&D review of Smallpox pipeline candidates. The report presents the current status of all major Smallpox therapeutic compounds. Detailed insights into...

October 2019 50 pages

Streptococcus pyogenes Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Streptococcus pyogenes Infections Drug pipeline report- 2020 is an annual R&D review of Streptococcus pyogenes Infections pipeline candidates. The report presents the current status of all major Strep...

October 2019 50 pages

Tetanus Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Tetanus Drug pipeline report- 2020 is an annual R&D review of Tetanus pipeline candidates. The report presents the current status of all major Tetanus therapeutic compounds. Detailed insights into Tet...

October 2019 70 pages

Tinea pedis (Athlete Foot) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Tinea pedis (Athlete Foot) Drug pipeline report- 2020 is an annual R&D review of Tinea pedis (Athlete Foot) pipeline candidates. The report presents the current status of all major Tinea pedis (Athlet...

October 2019 40 pages

Toxoplasmosis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Toxoplasmosis Drug pipeline report- 2020 is an annual R&D review of Toxoplasmosis pipeline candidates. The report presents the current status of all major Toxoplasmosis therapeutic compounds. Detailed...

October 2019 40 pages

Tularemia Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Tularemia Drug pipeline report- 2020 is an annual R&D review of Tularemia pipeline candidates. The report presents the current status of all major Tularemia therapeutic compounds. Detailed insights in...

October 2019 40 pages

Typhoid Fever Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Typhoid Fever Drug pipeline report- 2020 is an annual R&D review of Typhoid Fever pipeline candidates. The report presents the current status of all major Typhoid Fever therapeutic compounds. Detailed...

October 2019 50 pages

Vancomycin Resistant Enterococcus (VRE) faecium Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Vancomycin Resistant Enterococcus (VRE) faecium Infections Drug pipeline report- 2020 is an annual R&D review of Vancomycin Resistant Enterococcus (VRE) faecium Infections pipeline candidates. The rep...

October 2019 70 pages

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug pipeline report- 2020 is an annual R&D review of Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline candidates. The...

October 2019 50 pages

Ventilator Associated Pneumonia (VAP) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Ventilator Associated Pneumonia (VAP) Drug pipeline report- 2020 is an annual R&D review of Ventilator Associated Pneumonia (VAP) pipeline candidates. The report presents the current status of all maj...

October 2019 80 pages

West Nile Virus Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

West Nile Virus Infections Drug pipeline report- 2020 is an annual R&D review of West Nile Virus Infections pipeline candidates. The report presents the current status of all major West Nile Virus Inf...

October 2019 50 pages

Western Equine Encephalitis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Western Equine Encephalitis Drug pipeline report- 2020 is an annual R&D review of Western Equine Encephalitis pipeline candidates. The report presents the current status of all major Western Equine En...

October 2019 40 pages

Yellow Fever Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

US$ 1,529.00

Yellow Fever Drug pipeline report- 2020 is an annual R&D review of Yellow Fever pipeline candidates. The report presents the current status of all major Yellow Fever therapeutic compounds. Detailed in...

October 2019 60 pages

Over-the-Counter (OTC) Drugs and Dietary Supplements: Opportunities for Consumer Goods Distributors

US$ 3,950.00

REPORT INCLUDES: An overview, scope and market landscape of Over-the-Counter (OTC) drugs and dietary supplement productsCoverage of regulatory needs and opportunities that can be found in the OTC dru...

October 2019 41 pages

Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry

US$ 5,500.00

REPORT SCOPE: The current report provides details about drug molecules that have been or will be launched in the market in 2019. This report highlights information and insights on the molecules. The...

September 2019 127 pages

Osteoporosis Drugs Market – By Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulator, RANK Ligand Inhibitors, Biosimilars, and Others), By Regions (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast up to 2025

US$ 3,250.00

Global Osteoporosis Drugs Market: Forecast up to 2025 [70 pages report] This market research report includes a detailed segmentation of the global osteoporosis drugs market – by drug class (Bisphospho...

September 2019 70 pages

Cystic Fibrosis Drugs Market By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements, and Others), By Route of Application (Oral, Inhalation and Intravenous), By Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast up to 2025

US$ 3,250.00

Global Cystic Fibrosis Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025 [75 pages report] This market research report includes a detailed segmentation of the global c...

September 2019 75 pages

Analgesics Global Report

US$ 950.00

... Year to Next 7 years. This data is found in about 200 tables. ANALGESICS 1. Analgesics 2. ASPRIN 3. ASPRIN - SOLUBLE 4. PARACETAMOL 5. COMPOUNDS This report is from a Market ... Coupon value of $300. ANALGESICS WORLD REPORT DATABASE EDITION The Market for Analgesics in each country by Products & Services. The Analgesics World Report covers ...

September 2019 451 pages

Filters

Clear all